The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2.
Open accessAbstract
Spleen cells from C57BL/6 mice immunized in vivo with a syngeneic Friend virus-induced leukemia, FBL-3, were specifically activated by culture for 7 d with FBL-3, then nonspecifically induced to proliferate in vitro for 12 d by addition of supernatants from concanavalin A-stimulated lymphocytes containing interleukin 2 (IL-2). Such long-term cultured T lymphocytes have previously been shown to specifically lyse FBL-3 and to mediate specific adoptive therapy of advanced disseminated FBL-3 when used as an adjunct to cyclophosphamide (CY) in adoptive chemoimmunotherapy. Because the cultured cells are dependent upon IL-2 for proliferation and survival in vitro, their efficacy in vivo is potentially limited by the availability of endogenous IL-2. Thus, the aim of the current study was to determine whether exogenously administered purified IL-2 could augment the in vivo efficacy of long-term cultured T lymphocytes. Purified IL-2 alone or as an adjunct to CY as ineffective in tumor therapy. However, IL-2 was extremely effective in augmenting the efficacy of IL-2-dependent long-term cultured T lymphocytes in adoptive chemoimmunotherapy. The mechanism by which IL-2 functions in vivo is presumably by promoting in vivo growth and/or survival of adoptively transferred cells. This assumption was supported by the findings that IL-2 did not enhance the modest therapeutic efficacy of irradiated long-term cultured cells that were incapable of proliferating in the host and was ineffective in augmenting the in vivo efficacy of noncultured immune cells that are not immediately dependent upon exogenous IL-2 for survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A generalized Wilcoxon test for comparing arbitrarily singly-censored samples
Gehan, E. A. (1965) · Biometrika · doi:10.1093/biomet/52.1-2.203 · Cited by 3,406
T Cell Growth Factor: Parameters of Production and a Quantitative Microassay for Activity
Gillis, S., Ferm, M. M., Ou, W., & Smith, K. A. (1978) · The Journal of Immunology · doi:10.4049/jimmunol.120.6.2027 · Cited by 3,273
Self-citationA generalized Kruskal-Wallis test for comparing K samples subject to unequal patterns of censorship
BRESLOW, N. (1970) · Biometrika · doi:10.1093/biomet/57.3.579 · Cited by 1,411
Long term culture of tumour-specific cytotoxic T cells
GILLIS, S., & SMITH, K. A. (1977) · Nature · doi:10.1038/268154a0 · Cited by 1,386
Self-citationContinuous proliferation of murine antigen-specific helper T lymphocytes in culture.
Watson, J. (1979) · The Journal of experimental medicine · doi:10.1084/jem.150.6.1510 · Cited by 517
Functional and Morphologic Characterization of Human T Cells Continuously Grown in Vitro
Ruscetti, F. W., Morgan, D. A., & Gallo, R. C. (1977) · The Journal of Immunology · doi:10.4049/jimmunol.119.1.131 · Cited by 408
Fujimoto, S., Greene, M. I., & Sehon, A. H. (1976) · PubMed · Cited by 340
Wagner, H., & Röllinghoff, M. (1978) · The Journal of experimental medicine · doi:10.1084/jem.148.6.1523 · Cited by 327
Greenberg, P. D., Cheever, M. A., & Fefer, A. (1981) · The Journal of experimental medicine · doi:10.1084/jem.154.3.952 · Cited by 312
Self-citationPassive Immunotherapy of Cancer in Animals and Man
(1977) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60637-5 · Cited by 243
Cited by
Rosenberg, S. A., Mulé, J. J., Spiess, P. J., Reichert, C. M., & Schwarz, S. L. (1985) · The Journal of experimental medicine · doi:10.1084/jem.161.5.1169 · Cited by 745
Mulé, J. J., Shu, S., Schwarz, S. L., & Rosenberg, S. A. (1984) · Science · doi:10.1126/science.6332379 · Cited by 688
Adoptive-cell-transfer therapy for the treatment of patients with cancer
Dudley, M. E., & Rosenberg, S. A. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1167 · Cited by 660
Gansbacher, B., Zier, K., Daniels, B., Cronin, K., Bannerji, R., & Gilboa, E. (1990) · The Journal of experimental medicine · doi:10.1084/jem.172.4.1217 · Cited by 620
Greenberg, P. D. (1991) · Advances in Immunology · doi:10.1016/s0065-2776(08)60778-6 · Cited by 603
Self-citationBiological Activity of Recombinant Human Interleukin-2 Produced in Escherichia coli
Rosenberg, S. A., Grimm, E. A., McGrogan, M., Doyle, M., Kawasaki, E., Koths, K., & Mark, D. F. (1984) · Science · doi:10.1126/science.6367046 · Cited by 595
Adoptive T cell therapy for cancer in the clinic
June, C. H. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32446 · Cited by 553
Klebanoff, C. A., Khong, H. T., Antony, P. A., Palmer, D. C., & Restifo, N. P. (2005) · Trends in Immunology · doi:10.1016/j.it.2004.12.003 · Cited by 469
Rosenberg, S. A., Lotze, M. T., Yang, J. C., Linehan, W. M., Seipp, C., Calabro, S., Karp, S. E., Sherry, R. M., Steinberg, S., & White, D. E. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.12.1863 · Cited by 374
Mazumder, A., & Rosenberg, S. A. (1984) · The Journal of experimental medicine · doi:10.1084/jem.159.2.495 · Cited by 369
Natural killer cells and cancer
Brittenden, J., Heys, S. D., Ross, J., & Eremin, O. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960401)77:7<1226::aid-cncr2>3.0.co;2-g · Cited by 319
Cancer Immunotherapy Using Interleukin-2 and Interleukin-2-Activated Lymphocytes
Rosenberg, S. A., & Lotze, M. T. (1986) · Annual Review of Immunology · doi:10.1146/annurev.iy.04.040186.003341 · Cited by 314
Zhang, M., Liu, C., Tu, J., Tang, M., Ashrafizadeh, M., Nabavi, N., Sethi, G., Zhao, P., & Liu, S. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02305-x · Cited by 259
The Role of Tumor Microenvironment in Cancer Immunotherapy
Frankel, T., Lanfranca, M. P., & Zou, W. (2017) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-67577-0_4 · Cited by 173
Metadata
- Authors
- Cheever, M. A., Greenberg, P. D., Fefer, A., & Gillis, S.
- Venue
- The Journal of experimental medicine
- Publisher
- Rockefeller University Press
- Published
- 1982-04-01
- Volume
- 155
- Issue
- 4
- Pages
- 968-980
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2133818380
- Cited by
- 265
- References
- 13
- FWCI
- 12.45
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.